 Minerva Neurosciences Inc NASDAQ: NERV announced results from a bioequivalence study comparing roluperidone formulations used in Phase 2b and Phase 3 trials and the planned commercial formulation. Related Link: Minervas Schizophrenia Candidate Shows Long Term Improvement In Negative Symptoms, Functioning 